Impressive Rapid Complete Response on FDG PET/CT to BRAF Inhibitors in a Metastatic Melanoma With Massive Tumor Burden.
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Fluorodeoxyglucose F18
Humans
Melanoma
/ drug therapy
Oximes
/ therapeutic use
Positron Emission Tomography Computed Tomography
Proto-Oncogene Proteins B-raf
Pyridones
/ therapeutic use
Pyrimidinones
/ therapeutic use
Skin Neoplasms
/ drug therapy
Tumor Burden
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
pubmed:
8
10
2021
medline:
13
1
2022
entrez:
7
10
2021
Statut:
ppublish
Résumé
Recent advances in the development of innovative treatments for MM (metastatic melanoma) significantly improved survival. BRAF inhibitor-targeted therapies are also indicated in stage IV BRAF-mutant melanoma, especially dabrafenib and trametinib in combination. The authors present here an impressive rapid (1 month) complete metabolic response on FDG PET/CT to BRAF inhibitors of an MM with a massive tumor burden estimated at more than 10 kg.
Identifiants
pubmed: 34619701
doi: 10.1097/RLU.0000000000003922
pii: 00003072-202202000-00059
doi:
Substances chimiques
Oximes
0
Pyridones
0
Pyrimidinones
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e180-e181Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med . 2019;381:626–636.
Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol . 2018;19:1480–1492.
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med . 2011;364:2507–2516.
Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med . 2012;367:107–114.
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med . 2014;371:1877–1888.
Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet . 2015;386:444–451.
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med . 2015;372:30–39.
Salaün PY, Abgral R, Malard O, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging . 2020;47:28–50.